Why 'blood products' needs to be broken down, not treated as one thing
Whole blood is rarely transfused these days. Patients more commonly receive separated components. These include red cells, platelets, plasma or cryoprecipitate. Each has a different clinical purpose and risk profile.
A medical consent form that only says 'blood transfusion' without naming the specific product obscures exactly what is being agreed to. This matters enormously for patients with religious or personal objections to specific fractions.
List the product or products proposed explicitly. Where a patient has specific preferences, record those by product. This is better than a single blanket yes or no. Proper documentation ensures informed interview consent principles are followed.
What a blood transfusion consent form must record about risks and alternatives
The common risks of transfusion include mild allergic reactions or fever. Rarer but serious events such as lung injury or infection transmission should also be discussed. Patients must weigh these against the risk of not being transfused.
The form should record that both sides of that balance were discussed. In many cases, the risk of declining is the more significant clinical concern. This is especially true during a surgery consent form discussion for urgent procedures.
Alternatives worth raising include iron replacement therapy for anaemia or other blood-conserving surgical techniques. Cell salvage is another option. Not every alternative will be appropriate for every patient, but the discussion and outcome must be documented.
Cell salvage as a distinct decision
Intra-operative cell salvage involves collecting a patient's own blood lost during surgery. It is then filtered and returned to them. This is clinically and ethically distinct from receiving donor blood. Many patients decline donor transfusion but accept cell salvage.
Because of this, cell salvage deserves its own separate consent line. It should not be bundled into a general transfusion consent or refusal. Conflating the two can lead to a patient's own blood being needlessly discarded during surgery.
Advance refusal: getting the specificity right
An advance refusal of blood products is only useful in an emergency if it is specific. It must be clear enough to act on quickly under pressure. Vague wording such as 'I do not want a transfusion' leaves clinicians guessing about specifics.
A properly specific refusal names the exact products declined. It records anything the patient is willing to accept. Many patients accept cell salvage or certain plasma fractions while declining whole blood or platelets. It should state if the refusal holds in life-threatening emergencies.
This section should be dated, signed, and witnessed if required. It may be relied upon when the patient cannot be asked to confirm. Review it periodically. Update it immediately if circumstances change, much like a general medical consent form for routine care.
Emergencies and consent obtained under time pressure
Where a transfusion is needed urgently, a full conversation may not be possible. Clinical teams generally proceed based on the patient's best interests. This is informed by any advance refusal already on record in their medical records.
This is exactly why an advance refusal needs to be easily findable. It should be lodged before an emergency arises. Discussing these preferences for the first time during an emergency is far from ideal. Proper documentation prevents confusion when every second counts.
Capacity and who can refuse on a patient's behalf
An advance refusal is only valid if made by a patient with capacity. This refers to their ability to make that decision at the time it was recorded. If a patient later loses capacity, a properly made prior refusal still applies.
Refusal by a parent on behalf of a child is treated differently. Clinical teams and courts may review these decisions if they conflict with the child's best interests. This form is not for that situation. Seek specialist guidance for paediatric cases involving X-ray consent or other treatments.
Country differences: US transfusion consent versus UK NHS practice
Transfusion is one of the most tightly regulated treatments in medicine, and the oversight bodies differ by country. Adapt the blood transfusion consent form to the framework that applies where the transfusion is given.
Advance refusal wording should also reflect local law: an advance directive in the US, an advance decision to refuse treatment under the Mental Capacity Act in England and Wales, and provincial or state equivalents elsewhere. See the surgery consent form page for how this interacts with operative consent.
United States
Blood establishments and hospital transfusion services are regulated by the FDA, with AABB standards governing hospital practice and The Joint Commission expecting documented informed consent that names risks, benefits and alternatives.
Many states have specific statutes requiring patients to be offered information about autologous and directed donation before an elective transfusion, and reactions are reported through the hospital's haemovigilance programme to the FDA.
United Kingdom (NHS)
NHS transfusions follow the Blood Safety and Quality Regulations, NHS Blood and Transplant supply rules, and NICE guidance on transfusion thresholds, with consent recorded in the patient's notes and adverse events reported to SHOT and the MHRA.
UK trusts also apply a positive-patient-identification bedside check and, for planned surgery, patient blood management pathways that treat iron therapy and cell salvage as first-line alternatives before donor blood.
Canada, Australia and New Zealand
Canadian Blood Services and Héma-Québec supply components under Health Canada regulation, Australia uses the National Blood Authority Patient Blood Management Guidelines with Lifeblood supply, and New Zealand follows NZ Blood Service standards.